\n| \n \n(dollars in millions, except per share amounts)<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n Change (%)<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| \n \nAcute Inpatient Psychiatric Facilities<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n524.8<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n471.5<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n11<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nSpecialty Treatment Facilities<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n136.0<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n148.1<\/p>\n<\/td>\n | | \n\n \n(8<\/p>\n<\/td>\n | \n \n%)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nComprehensive Treatment Centers<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n141.1<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$<\/p>\n<\/td>\n | \n \n144.5<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n(2<\/p>\n<\/td>\n | \n \n%)<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nResidential Treatment Centers<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n93.4<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n87.5<\/p>\n<\/td>\n | | \n\n \n7<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| \n Total Revenue<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 895.3<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 851.6<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 5<\/b><\/p>\n<\/td>\n | \n %<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n \nReported Net Income<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n34.5<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n36.2<\/p>\n<\/td>\n | | \n\n \n(5<\/p>\n<\/td>\n | \n \n%)<\/p>\n<\/td>\n<\/tr>\n | \n| \n Adjusted EBITDA<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 176.4<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 173.0<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 2<\/b><\/p>\n<\/td>\n | \n %<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Reported EPS<\/b><\/p>\n<\/td>\n | | \n\n $<\/b><\/p>\n<\/td>\n | \n 0.38<\/b><\/p>\n<\/td>\n | | \n\n $<\/b><\/p>\n<\/td>\n | \n 0.40<\/b><\/p>\n<\/td>\n | | \n\n (5<\/b><\/p>\n<\/td>\n | \n %)<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Adjusted EPS<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 0.60<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n $<\/b><\/p>\n<\/td>\n | \n 0.72<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n (17<\/b><\/p>\n<\/td>\n | \n %)<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Discussion of Third Quarter Results<\/b><\/p>\n \nTotal revenue in the third quarter was $895.3 million, which was an increase of 5.1% compared with the prior-year period. Facilities closed over the last twelve months represented a negative 1.3% impact to reported revenue growth in the quarter.<\/p>\n \nSame-facility revenue increased 5.2% compared with the prior-year period. Same-facility patient days increased 1.1%, and same-facility revenue per patient day increased 4.0%.<\/p>\n \nAcute inpatient psychiatric facility (\u201cAcute\u201d) revenue was $524.8 million, which was an increase of 11.3% compared with the prior-year period. Third quarter Acute inpatient volumes increased 7.5% compared with the prior-year period, driven primarily by expanded capacity from both newly constructed and existing facilities.<\/p>\n \nSpecialty treatment facility (\u201cSpecialty\u201d) revenue was $136.0 million, a decrease of 8.2% compared with the prior-year period. The revenue decline was related to Specialty facilities in Pennsylvania and the impact from having closed several Specialty facilities over the last 12 months.<\/p>\n \nComprehensive treatment center (\u201cCTC\u201d) revenue was $141.1 million, which was a decrease of 2.3% compared with the prior-year period. Residential treatment center (\u201cRTC\u201d) revenue was $93.4 million, an increase of 6.7% compared with the prior-year period.<\/p>\n \nTotal operating expenses were $728.1 million in the third quarter of 2026, an increase of 6.4% compared with the prior-year period.<\/p>\n \nSalaries, wages and benefits were $490.3 million for the third quarter of 2026, an increase of 6.1% compared with the prior-year period. The increase is primarily due to new facility openings, as well as routine annual wage increases. Same-facility salaries, wages and benefits increased by 4.3%.<\/p>\n \nAdjusted EBITDA for the third quarter was $176.4 million, compared with $173.0 million in the prior-year period. Third quarter 2026 Adjusted EBITDA includes a favorable pre-tax benefit related to an accrual for expected payments from the Florida supplemental payment program year ended September 30, 2026, which was $13.4 million compared to $5.6 million included in the Company’s previous guidance.<\/p>\n Development Activity<\/b><\/p>\n \nThe Company added 220 licensed beds during the third quarter, including a 144-bed de novo facility near Jacksonville, Florida and 76 beds added to existing facilities. Additionally, the Company opened one new CTC location and closed one existing CTC location during the quarter.<\/p>\n Cash and Liquidity<\/b><\/p>\n \nAs of September 30, 2026, the Company had $163.3 million in cash and cash equivalents and $710.1 million available under its $1.0 billion revolving credit facility. As of September 30, 2026, Acadia\u2019s net leverage ratio was 3.9x Adjusted EBITDA, calculated in accordance with its Credit Agreement as disclosed in the Company\u2019s latest periodic reports and other filings with the Securities and Exchange Commission (\u201cSEC\u201d).<\/p>\n 2026 Financial Guidance<\/b><\/p>\n \nAcadia today updated its financial guidance for 2026, as follows:<\/p>\n \n\n| \n \n\u00a0<\/p>\n<\/td>\n | | \n\n Full Year 2026<\/span><\/p>\nNovember Guidance Range<\/span><\/p>\n<\/td>\n | \n Full Year 2026<\/span><\/p>\nJuly Guidance Range<\/span><\/p>\n<\/td>\n<\/tr>\n\n| \n \nRevenue<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$3.44 to $3.46 billion<\/p>\n<\/td>\n | \n \n$3.40 to $3.45 billion<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted EBITDA<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$615 to $625 million<\/p>\n<\/td>\n | \n \n$590 to $615 million<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nAdjusted earnings per diluted share<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$1.70 to $1.80<\/p>\n<\/td>\n | \n \n$1.45 to $1.60<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nOperating Cash Flow<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$375 to $400 million<\/p>\n<\/td>\n | \n \n$350 to $400 million<\/p>\n<\/td>\n<\/tr>\n | \n| \n \nCapital expenditures<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n$210 to $230 million<\/p>\n<\/td>\n | \n \n$235 to $255 million<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nThe Company\u2019s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.<\/p>\n Conference Call<\/b><\/p>\n \nAcadia will hold a conference call to discuss its third quarter financial results at 8:00 a.m. Central Time \/ 9:00 a.m. Eastern Time on Thursday, November 5, 2026. A live webcast of the conference call will be available at www.acadiahealthcare.com<\/a> in the \u201cInvestors\u201d section of the website. The archived webcast will be available after the call has ended.<\/p>\nAbout Acadia<\/b><\/p>\n \nAcadia Healthcare is the largest stand-alone behavioral healthcare company in the United States, providing mental health and addiction treatment services across a comprehensive continuum of care that includes inpatient psychiatric hospitals, specialty treatment facilities, RTCs, and outpatient clinics. Acadia operates 280 behavioral health facilities across 40 states and Puerto Rico and serves more than 85,000 patients daily. Guided by its mission, Acadia provides paths to healing through evidence-based treatment and compassionate care that inspires hope, improves lives and elevates communities.<\/p>\n Description of Business<\/b><\/p>\n \nUnless the context otherwise requires, all references herein to \u201cAcadia,\u201d \u201cAcadia Healthcare,\u201d \u201cthe Company,\u201d \u201cwe,\u201d \u201cus\u201d or \u201cour\u201d mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries conduct healthcare and management operations. The terms \u201cfacilities,\u201d \u201ccenters,\u201d \u201cclinics,\u201d and \u201chospitals\u201d refer to entities owned, operated, or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to \u201cemployees\u201d refer to employees of subsidiaries of Acadia Healthcare Company, Inc.<\/p>\n Forward-Looking Information<\/b><\/p>\n \nThis press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to our strategy, growth and anticipated operating results for future periods. Generally, words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201ccontinue\u201d and \u201cbelieve\u201d or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties, and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia\u2019s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions or delays in payments received by Acadia from government, commercial and other third-party payors or denials of claims for payment, including, without limitation, because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (the \u201cOBBBA\u201d) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) changes in expectations resulting from actuarial and other reviews of Acadia\u2019s liability reserves and other aspects of its business; (vii) potential disruptions to our information technology systems or adverse impacts of a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to the OBBBA\u2019s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia\u2019s periodic reports and other filings with the SEC.<\/p>\n \n\nAcadia Healthcare Company, Inc.<\/b><\/td>\n<\/tr>\n\nCondensed Consolidated Statements of Income<\/b><\/td>\n<\/tr>\n\n(Unaudited)<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \nThree Months Ended September 30,<\/b><\/td>\n | | \nNine Months Ended September 30,<\/b><\/td>\n<\/tr>\n\n | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n(In thousands, except per share amounts)<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Revenue<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n895,309<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n851,573<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n2,589,950<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n2,491,310<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Salaries, wages and benefits (including equity-based compensation expense of $9,246, $6,031, $28,192 and $25,257, respectively)<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n490,267<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n462,169<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n1,431,402<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n1,359,857<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Professional fees\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 58,664<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 51,478<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 167,621<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 147,146<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Supplies\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 31,504<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 30,412<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 91,192<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 87,286<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Rents and leases\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 11,933<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 11,736<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 35,510<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 36,002<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other operating expenses\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 135,738<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 128,787<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 422,564<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 377,203<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Depreciation and amortization\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 53,134<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 47,468<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 155,987<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 143,495<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Interest expense, net<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 37,278<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 36,619<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 113,786<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 100,939<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Debt extinguishment costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,269<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Legal settlements (gain) expense<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (7,151<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 6,600<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,504<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Loss on impairment<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,546<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 10,910<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,452<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Loss (gain) on sale of property<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 189<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (3,392<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (8,715<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Transaction, legal and other costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 23,739<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 42,919<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 68,331<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 138,416<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total expenses\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n838,841<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n811,588<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,500,511<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,387,854<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Income before income taxes<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n56,468<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n39,985<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n89,439<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n103,456<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Provision for income taxes\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n17,818<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n1,668<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n34,065<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n18,139<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Net income<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n38,650<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n38,317<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n55,374<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n85,317<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Net income attributable to noncontrolling interests<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(4,164<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(2,071<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(5,855<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(10,570<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Net income attributable to Acadia Healthcare Company, Inc.<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n34,486<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n36,246<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n49,519<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n74,747<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Earnings per share attributable to Acadia Healthcare\u00a0Company, Inc. stockholders:\u00a0<\/td>\n | | \n | \n | \n | \n | \n | \n | \n | <\/tr>\n \n| Basic\u00a0<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.38<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.40<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.55<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.82<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Diluted\u00a0<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.38<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.40<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.54<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n0.82<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Weighted-average shares outstanding:\u00a0<\/td>\n | | \n | \n | \n | \n | \n | \n | \n | <\/tr>\n \n| Basic\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n90,888<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n90,414<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n90,747<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n90,794<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Diluted\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n91,746<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n90,584<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n91,452<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n91,255<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\nAcadia Healthcare Company, Inc.<\/b><\/td>\n<\/tr>\n\nCondensed Consolidated Balance Sheets<\/b><\/td>\n<\/tr>\n\n(Unaudited)<\/b><\/td>\n<\/tr>\n\n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \nSeptember 30,<\/b><\/td>\n | | \nDecember 31,<\/b><\/td>\n<\/tr>\n\n| \u00a0\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \u00a0\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | (In thousands)\u00a0<\/b><\/td>\n<\/tr>\n\n| \u00a0\u00a0<\/td>\n | | \n | \n | \n | <\/tr>\n \nASSETS\u00a0<\/b><\/td>\n<\/tr>\n\n| Current assets:\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | | \n\u00a0\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n<\/tr>\n | \n| Cash and cash equivalents\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n163,307<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n133,242<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Accounts receivable, net<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n501,385<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n440,604<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other current assets\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n216,624<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n240,293<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total current assets\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n881,316<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n814,139<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Property and equipment, net<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n3,048,638<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n3,111,212<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Goodwill\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n1,315,642<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n1,296,342<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Intangible assets, net\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n100,189<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n96,672<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Deferred tax assets<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,422<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,528<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Operating lease right-of-use assets<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n139,142<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n134,005<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other assets\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n67,241<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n72,550<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total assets\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n5,554,590<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n5,527,448<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \u00a0\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n | \n| \u00a0\u00a0<\/td>\n | | \n | \n | \n | <\/tr>\n \nLIABILITIES AND EQUITY\u00a0<\/b><\/td>\n<\/tr>\n\n| Current liabilities:\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n | \n| Current portion of long-term debt\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n32,500<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n28,438<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Accounts payable\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n138,557<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n150,403<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Accrued salaries and benefits\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n184,392<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n188,638<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Current portion of operating lease liabilities<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n21,739<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n21,160<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other accrued liabilities\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n174,842<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n136,555<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total current liabilities\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n552,030<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n525,194<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Long-term debt\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,319,859<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,471,529<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Deferred tax liabilities<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n93,639<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n66,605<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Operating lease liabilities<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n129,547<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n121,961<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other liabilities\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n207,147<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n201,607<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total liabilities\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n3,302,222<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n3,386,896<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Redeemable noncontrolling interests<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n229,876<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n191,592<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Equity:\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | | \n\u00a0\u00a0\u00a0\u00a0<\/td>\n | | <\/tr>\n \n| Common stock<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n909<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n905<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Additional paid-in capital\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,737,905<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,713,896<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Accumulated deficit<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n(716,322<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n(765,841<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Total equity\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n2,022,492<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \n \n1,948,960<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Total liabilities and equity\u00a0<\/td>\n | \u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n5,554,590<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | \u00a0\u00a0\u00a0\u00a0<\/td>\n | \n \n\u00a0$<\/p>\n<\/td>\n | \n \n5,527,448<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\nAcadia Healthcare Company, Inc.<\/b><\/td>\n<\/tr>\n\nCondensed Consolidated Statements of Cash Flows<\/b><\/td>\n<\/tr>\n\n(Unaudited)<\/b><\/td>\n<\/tr>\n\n| \u00a0\u00a0<\/td>\n | | \n | \n | \n | <\/tr>\n \n | \n | \nNine Months Ended September 30,<\/b><\/td>\n<\/tr>\n\n| \u00a0\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \u00a0\u00a0<\/td>\n | | \n(In thousands)<\/b><\/td>\n<\/tr>\n\n| Operating activities:\u00a0<\/b><\/td>\n | | \n | \n | \n | <\/tr>\n \n| Net income<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 55,374<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 85,317<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Adjustments to reconcile net income to net cash provided by operating activities:\u00a0<\/b><\/td>\n | | \n | \n | \n | <\/tr>\n \n| Depreciation and amortization\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 155,987<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 143,495<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Amortization of debt issuance costs\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,796<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,513<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Equity-based compensation expense<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 28,192<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 25,257<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Deferred income taxes<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 27,141<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,309<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Debt extinguishment costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,269<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Non-cash legal settlements expense<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 3,504<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Loss on impairment<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 10,910<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,452<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Loss (gain) on sale of property<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (3,392<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (8,715<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Other\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 639<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,907<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Change in operating assets and liabilities, net of effect of acquisitions:\u00a0<\/td>\n | | \n | \n | \n | <\/tr>\n \n| Accounts receivable, net<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (60,781<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (64,958<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Other current assets\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 43,992<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (17,590<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Other assets\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (1,976<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (10,865<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Accounts payable and other accrued liabilities<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 36,311<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 33,584<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Accrued salaries and benefits\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (10,138<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 5,158<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other liabilities\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 35,426<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 12,554<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Net cash provided by operating activities\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n321,481<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n218,191<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Investing activities:\u00a0<\/b><\/td>\n | | \n | \n | \n | <\/tr>\n \n| Cash paid for acquisitions, net of cash acquired\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (8,165<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Cash paid for capital expenditures\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (165,860<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (478,617<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Proceeds from sale of property and equipment<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 33,901<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 23,151<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Other\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (3,439<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (145<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Net cash used in investing activities\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(135,398<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(463,776<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Financing activities:\u00a0<\/b><\/td>\n | | \n | \n | \n | <\/tr>\n \n| Borrowings on long-term debt\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 1,200,000<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Borrowings on revolving credit facility<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 85,000<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 875,000<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Principal payments on revolving credit facility<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (215,000<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (1,035,000<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Principal payments on long-term debt\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (20,313<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (8,125<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Repayment of long-term debt<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (670,856<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Payment of debt issuance costs<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (18,615<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (4,150<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (3,953<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Repurchase of common stock<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (50,034<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Contributions from noncontrolling partners in joint ventures<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 2,759<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 5,000<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Distributions to noncontrolling partners in joint ventures<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (4,207<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (3,877<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Cash paid for contingent consideration<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (1,500<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Other<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (107<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 (67<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Net cash (used in) provided by financing activities\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(156,018<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n287,973<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Net increase in cash and cash equivalents<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n30,065<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n42,388<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Cash and cash equivalents at beginning of the period\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n133,242<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n76,305<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Cash and cash equivalents at end of the period\u00a0<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n163,307<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n118,693<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| \u00a0\u00a0<\/td>\n | | \n | \n | \n | <\/tr>\n \n| Effect of acquisitions:\u00a0<\/b><\/td>\n | | \n | \n | \n | <\/tr>\n \n| Assets acquired, excluding cash\u00a0<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n33,591<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n36,715<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Liabilities assumed\u00a0<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n\u00a0 \u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(1,193<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Redeemable noncontrolling interest resulting from an acquisition<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(33,591<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n(27,357<\/p>\n<\/td>\n | \n \n)<\/p>\n<\/td>\n<\/tr>\n | \n| Cash paid for acquisitions, net of cash acquired\u00a0<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n\u2014<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n8,165<\/p>\n<\/td>\n | \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\n| \n Acadia Healthcare Company, Inc.<\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n Operating Statistics (1)<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n\n| \n (Unaudited, $ in thousands except per Patient Day metrics)<\/b><\/p>\n<\/td>\n<\/tr>\n\n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n | \n | \nThree Months Ended September 30,<\/b><\/td>\n | | \nNine Months Ended September 30,<\/b><\/td>\n<\/tr>\n\n | \n | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | | \n\n % Change<\/b><\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2026<\/b><\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n 2025<\/b><\/p>\n<\/td>\n | | \n\n % Change<\/b><\/p>\n<\/td>\n<\/tr>\n\n| Same Facility Results (2)<\/td>\n | | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Revenue<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n883,212<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n839,629<\/p>\n<\/td>\n | | \n\n \n5.2<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n2,552,950<\/p>\n<\/td>\n | | \n\n \n$<\/p>\n<\/td>\n | \n \n2,454,772<\/p>\n<\/td>\n | | \n\n \n4.0<\/p>\n<\/td>\n | \n \n%\u00a0<\/p>\n<\/td>\n<\/tr>\n | \n| Patient Days<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n823,164<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n814,177<\/p>\n<\/td>\n | | \n\n \n1.1<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,390,199<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,362,771<\/p>\n<\/td>\n | | \n\n \n1.2<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Admissions<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n56,999<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n53,486<\/p>\n<\/td>\n | | \n\n \n6.6<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n163,099<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n153,142<\/p>\n<\/td>\n | | \n\n \n6.5<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \nAverage Length of Stay (3)<\/sup><\/td>\n | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n14.4<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n15.2<\/p>\n<\/td>\n | | \n\n \n-5.1<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n14.7<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n15.4<\/p>\n<\/td>\n | | \n\n \n-5.0<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Revenue per Patient Day<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,073<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,031<\/p>\n<\/td>\n | | \n\n \n4.0<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,068<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,039<\/p>\n<\/td>\n | | \n\n \n2.8<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Adjusted EBITDA<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n228,803<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n215,553<\/p>\n<\/td>\n | | \n\n \n6.1<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n629,230<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n639,573<\/p>\n<\/td>\n | | \n\n \n-1.6<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n\u00a0<\/td>\n<\/tr>\n | \n| Total Facility Results\u00a0<\/td>\n | | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | <\/tr>\n \n| Revenue<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n895,309<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n851,573<\/p>\n<\/td>\n | | \n\n \n5.1<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n2,589,950<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n2,491,310<\/p>\n<\/td>\n | | \n\n \n4.0<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Patient Days<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n836,495<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n830,165<\/p>\n<\/td>\n | | \n\n \n0.8<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,428,245<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n2,409,938<\/p>\n<\/td>\n | | \n\n \n0.8<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Admissions<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n58,272<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n54,450<\/p>\n<\/td>\n | | \n\n \n7.0<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n167,003<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n156,055<\/p>\n<\/td>\n | | \n\n \n7.0<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \nAverage Length of Stay (3)<\/sup><\/td>\n | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n14.4<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n15.2<\/p>\n<\/td>\n | | \n\n \n-5.8<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n14.5<\/p>\n<\/td>\n | | \n\n \n\u00a0<\/p>\n<\/td>\n | \n \n15.4<\/p>\n<\/td>\n | | \n\n \n-5.8<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Revenue per Patient Day<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,070<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,026<\/p>\n<\/td>\n | | \n\n \n4.3<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,067<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n1,034<\/p>\n<\/td>\n | | \n\n \n3.2<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n | \n| Adjusted EBITDA<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n216,162<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n210,779<\/p>\n<\/td>\n | | \n\n \n2.6<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n589,328<\/p>\n<\/td>\n | | \n\n \n\u00a0$<\/p>\n<\/td>\n | \n \n623,537<\/p>\n<\/td>\n | | \n\n \n-5.5<\/p>\n<\/td>\n | \n \n%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261104097026\/en\/583255\/3\/ACHC.jpg\")
<\/td>\n<\/tr>\n